Analysis of time-to-event and duration outcomes in neonatal clinical trials with twin births

被引:6
|
作者
Shaffer, Michele L. [1 ,2 ]
Hiriote, Sasiprapa [3 ]
机构
[1] Penn State Coll Med, Dept Publ Hlth Sci, Hershey, PA USA
[2] Penn State Coll Med, Dept Pediat, Hershey, PA USA
[3] Penn State Univ, Dept Stat, State Coll, PA USA
关键词
Correlated data; Frailty models; Robust variance; FRAILTY; MODEL;
D O I
10.1016/j.cct.2008.11.001
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
When conducting neonatal trials in pre-term and/or low-birth-weight infants, twins may represent 10-20% of the study sample. Frailty models and proportional hazards regression with a robust sandwich variance estimate are common approaches for handling correlated time-to-event data or duration outcomes that are subject to censoring. However, the operating characteristics of these methods for mixes of correlated and independent time-to-event data are not well established. Simulation studies were conducted to compare frailty models and proportional hazards regression models with a robust sandwich variance estimate to standard proportional hazards regression models to estimate the treatment effect in two-armed clinical trials. While overall frailty models showed the best performance, caution must be exercised as the interpretation of the parameters differs from the marginal models. Data from the National Institute of Child Health & Human Development sponsored PROPHET trial are used for illustration. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:150 / 154
页数:5
相关论文
共 50 条
  • [31] Principal stratification analysis of noncompliance with time-to-event outcomes
    Liu, Bo
    Wruck, Lisa
    Li, Fan
    BIOMETRICS, 2024, 80 (01)
  • [32] CAUSAL MEDIATION ANALYSIS FOR DICHOTOMOUS AND TIME-TO-EVENT OUTCOMES
    VanderWeele, T. J.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2011, 173 : S271 - S271
  • [33] Analysis of composite time-to-event endpoints in cardiovascular outcome trials
    Marceau West, Rachel
    Golm, Gregory
    Mehrotra, Devan, V
    CLINICAL TRIALS, 2024, 21 (05) : 576 - 583
  • [34] Time-to-event analysis
    Debanne, SM
    Rowland, DY
    GASTROINTESTINAL ENDOSCOPY, 2002, 55 (03) : 458 - 459
  • [35] A multistate platform model for time-to-event endpoints in oncology clinical trials
    Lin, Chih-Wei
    Nagase, Mario
    Doshi, Sameer
    Dutta, Sandeep
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (01): : 154 - 167
  • [36] Power considerations for clinical trials using multivariate time-to-event data
    Hughes, MD
    STATISTICS IN MEDICINE, 1997, 16 (08) : 865 - 882
  • [37] Heterogeneous treatment effects in stratified clinical trials with time-to-event endpoints
    Beisel, Christina
    Benner, Axel
    Kunz, Christina
    Kopp-Schneider, Annette
    BIOMETRICAL JOURNAL, 2017, 59 (03) : 511 - 530
  • [38] Adjusting for centre heterogeneity in multicentre clinical trials with a time-to-event outcome
    Munda, Marco
    Legrand, Catherine
    PHARMACEUTICAL STATISTICS, 2014, 13 (02) : 145 - 152
  • [39] Sample sizes for clinical trials with time-to-event endpoints and competing risks
    Schulgen, G
    Olschewski, M
    Krane, V
    Wanner, C
    Ruf, G
    Schumacher, M
    CONTEMPORARY CLINICAL TRIALS, 2005, 26 (03) : 386 - 396
  • [40] Considerations for analysis of time-to-event outcomes subject to competing risks in veterinary clinical studies
    Oyama, Mark A.
    Shaw, Pamela A.
    Ellenberg, Susan S.
    JOURNAL OF VETERINARY CARDIOLOGY, 2018, 20 (03) : 143 - 153